96 related articles for article (PubMed ID: 38732063)
21. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
22. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
[TBL] [Abstract][Full Text] [Related]
24. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
26. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
28. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
29. Acquired resistance mechanisms to osimertinib: The constant battle.
Zalaquett Z; Catherine Rita Hachem M; Kassis Y; Hachem S; Eid R; Raphael Kourie H; Planchard D
Cancer Treat Rev; 2023 May; 116():102557. PubMed ID: 37060646
[TBL] [Abstract][Full Text] [Related]
30. The Significance of Cancer Stem Cells and Epithelial-Mesenchymal Transition in Metastasis and Anti-Cancer Therapy.
Liang L; Kaufmann AM
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768876
[TBL] [Abstract][Full Text] [Related]
31. EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools.
Howell MC; Green R; Cianne J; Dayhoff GW; Uversky VN; Mohapatra S; Mohapatra S
J Biomol Struct Dyn; 2023 Nov; 41(19):9808-9827. PubMed ID: 36524419
[TBL] [Abstract][Full Text] [Related]
32. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
Piccirillo MC; Bonanno L; Garassino MC; Esposito G; Dazzi C; Cavanna L; Burgio MA; Rosetti F; Rizzato S; Morgillo F; Cinieri S; Veccia A; Papi M; Tonini G; Gebbia V; Ricciardi S; Pozzessere D; Ferro A; Proto C; Costanzo R; D'Arcangelo M; Proietto M; Gargiulo P; Di Liello R; Arenare L; De Marinis F; Crinò L; Ciardiello F; Normanno N; Gallo C; Perrone F; Gridelli C; Morabito A
J Thorac Oncol; 2022 Sep; 17(9):1086-1097. PubMed ID: 35659580
[TBL] [Abstract][Full Text] [Related]
33. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
Heitzer E; van den Broek D; Denis MG; Hofman P; Hubank M; Mouliere F; Paz-Ares L; Schuuring E; Sültmann H; Vainer G; Verstraaten E; de Visser L; Cortinovis D
ESMO Open; 2022 Apr; 7(2):100399. PubMed ID: 35202954
[TBL] [Abstract][Full Text] [Related]
34. Dynamic EMT: a multi-tool for tumor progression.
Brabletz S; Schuhwerk H; Brabletz T; Stemmler MP
EMBO J; 2021 Sep; 40(18):e108647. PubMed ID: 34459003
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer.
Zhang N; Ng AS; Cai S; Li Q; Yang L; Kerr D
Lancet Oncol; 2021 Aug; 22(8):e358-e368. PubMed ID: 34339656
[TBL] [Abstract][Full Text] [Related]
36. Lung cancer.
Thai AA; Solomon BJ; Sequist LV; Gainor JF; Heist RS
Lancet; 2021 Aug; 398(10299):535-554. PubMed ID: 34273294
[TBL] [Abstract][Full Text] [Related]
37. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Kashima Y; Shibahara D; Suzuki A; Muto K; Kobayashi IS; Plotnick D; Udagawa H; Izumi H; Shibata Y; Tanaka K; Fujii M; Ohashi A; Seki M; Goto K; Tsuchihara K; Suzuki Y; Kobayashi SS
Cancer Res; 2021 Sep; 81(18):4835-4848. PubMed ID: 34247147
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
